The Stem Cell Transplant Daily
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Related Articles
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati
Yuval Noah Harari argues that AI has hacked the operating system of human civilisation
Storytelling computers will change the course of human history, says the historian and philosopher
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for…
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy
Key Points. Despite the high initial rates of response to anti-BCMA CAR-T cell therapy in myeloma, those responses are frequently short-lived.Exhausted CD4
Humans are imperfect, inconsistent decision-makers
In their new book, Daniel Kahneman, Olivier Sibony and Cass Sunstein offer strategies for improvement
Two Brains Running (Published 2011)
In the conflict between intuitive and rational decision-making, which side wins?